There's no reason to think that if you treat hundreds of thousands of people, there wouldn't be a spectrum of responses. Based on the available evidence, though, Drucker emphasized it would be an extremely rare side effect
We continue to evaluate future development options for retatrutide, but have not announced development plans for these types of indications at this point in time." "Retatrutide is an investigational molecule that Lilly is studying for the treatment of obesity, obstructive sleep apnea (OSA), knee osteoarthritis and type 2 diabetes
BPC-157 promotes angiogenesis, which raises questions about use in individuals with active cancers where blood vessel growth could support tumor progression
The most commonly reported side effects are gastrointestinal and include nausea, vomiting, diarrhoea, and abdominal discomfort
Thats no way to live.About 6 months in, everything changed, I felt like I was in my 20s again
In 2024, tirzepatide became the first GLP-1 medication FDA-approved for moderate-to-severe OSA in adults with obesity (ref)